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Abstract 
Although clients diagnosed with colorectal cancer (CRC) are receiving more advanced 
and successful chemotherapy treatments, the side effects of these treatments continue to 
cause anxiety, discomfort, pain, and a diminished quality of life. Treatments must be 
developed to avoid some of the most unpleasant symptoms a client experiences as a result 
of these treatments. The purpose of this study was to examine the incidence of 
constipation related to the treatment of chemotherapy-induced nausea and vomiting 
(CINV) and to identify treatments that are successful in managing constipation while 
maintaining effective control of CINV. Constipation can be a significant problem with a 
negative impact on lifestyle during chemotherapy and needs aggressive management. Use 
of ondansetron as an antiemetic is associated with the development of constipation. A 
retrospective study was performed to identify the rate of constipation among a cohort of 
CRC clients and to determine effective treatment of constipation in the CRC client 
undergoing chemotherapy. Results of the study include increased rate of constipation in 
the study group, and limited documentation of symptoms and treatments. 
The study provided evidence that constipation is a significant side effect of CINV 
treatment with ondansetron and requires a comprehensive history to determine etiology. 
Communication is an important aspect of care, with the Clinical Nurse Specialist (CNS) 
informing staff of client history and insuring continuity of care. Implications and 
recommendations are identified and discussed. 
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Maintaining Quality Management of Chemotherapy-Induced Nausea and 
Vomiting with Minimal Constipation 
Background and Problem Statement 
Oncology cancer treatments have evolved over the last 30 years. Clients are now 
interpreting a cancer diagnosis as a chronic disease rather than an end of life experience. 
Approximately 55% of cancer patients survive five years, meaning that many clients 
become long-term survivors, a phenomenon made possible by the development of new 
therapies (Jefford et al. , 2011). CINV is a serious problem associated with poor health-
related quality of life (Likun, Xiang, Yi, Xin, &Tao, 2011 ). Approximately 70-80% of 
cancer clients receiving chemotherapy experience nausea, vomiting, or both symptoms 
(Rangwala, Zafar, & Abernethy, 2012). Frequently, when clients are interviewed just 
prior to beginning therapy, the one fear commonly identified, second only to hair loss, is 
tlie fear of feeling sick and vomiting (Likun et al. , 2011). Anti-nausea medications have 
provided much relief from the undesirable chemotherapy side effects: nausea and 
vomiting. The development of a new classification of drugs, the 5-HT3 inhibitors, to 
manage CINV has given many oncology clients the opportunity to receive the most 
effective treatment with minimal side effects. The use of this highly effective antiemetic 
therapy has allowed administration of chemotherapy in the ambulatory, outpatient setting 
(Lohr, 2008). As with any medication, there can be undesirable side effects. One very 
disrupting, and at times painful, side effect of the 5HT-3 medications is constipation. 
The clinician must consider the client' s presenting symptoms and the differential 
diagnosis of constipation when the client is receiving chemotherapy treatment. 
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Constipation is a distressing condition for cancer patients and is frequently under 
diagnosed (Nagaviroj , Yong, Fassbender, Zhu, & Onechuk, 2011). Constipation can be 
more distressing to clients than pain and can cause some clients to decline further 
treatments (Rangwala et al., 2012). Constipation is usually caused by a combination of 
poor oral intake, decreased physical activity, and drugs that have a neuropathic effect 
such as opiate pain medications, antiemetic medications, antidepressants, 
antihypertensive medications, and some chemotherapeutic agents (Rangwala et al., 
2012). These agents are important contributors to constipation because they slow 
intestinal transit time (Shafi & Bresalier, 2010). In clients who have a more advanced 
colorectal cancer, constipation may be suggestive of disease progression and may lead to 
life-threatening complications (Farjardo, Cremonini, & Talley, 2006). Other 
gastrointestinal abnormalities need to be ruled out prior to diagnosing constipation as due 
to treatment for CINV. Electrolyte imbalances and other reversible causes should be 
treated. Drugs contributing to constipation need to be avoided if they are not necessary 
for effective treatment of the client's problem. The impact of the symptoms of 
constipation on the quality of life of a cancer client is often greater than for those not 
affected by the disease. The oncology community frequently affected by this undesirable 
side effect is the CRC clientele. Colorectal clients are vulnerable to constipation 
secondary to necessary treatment, and this symptom is particularly problematic in this 
group (Farjardo et al. , 2006). 
Clients with CRC are generally treated with moderately emetogenic therapies, 
which require the use of anti-nausea medications. Many clients also need to take 
narcotics for pain; both contribute to constipation which is painful , decreases quality of 
life (QOL), and results in/leads to weight loss and depression (Likun et al. , 2011 ). 
Recognition of concomitant psychological stressors should be considered as part ofthe 
client's plan of care (POC) (Farjardo et al. , 2006). Assuring that the symptom of 
constipation is prevented when possible and/or effectively managed is an important 
nursing intervention that has been understudied in this population (Farjardo et al. , 2006). 
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Literature Review 
A systematic review of the literature was performed using PubMed, CINAHL and 
OVID databases. Internet sites relevant to this review included www.American Cancer 
Society, Up-To-Date and cancer.org. Keywords searched included: cancer, hair loss, 
constipation, chronic disease, life expectancy, chemotherapy, nausea, vomiting, emesis, 
colon cancer, rectal cancer, CRC, and nursing. Search terms focused on constipation in 
CRC undergoing treatment with moderately emetogentic chemotherapy and constipation. 
By combining several keywords, the literature search was more concise yielding more 
specific articles. Literature will focus on CRC, chemotherapy, chemotherapy-induced 
side effects, constipation, and constipation in clients with CRC, antiemetic treatment, and 
their impact on the role of the CNS. 
Colorectal Cancer: Background and Epidemiology 
In 2007, The National Program of Cancer Registries identified CRC as the 4th 
most commonly diagnosed cancer in Rhode Island (Cancer.org). In 2011 , the American 
Cancer Society (ACS) ranked CRC as the third most frequently diagnosed cancer and 
third leading cause of cancer death in both men and women in the United States. 
Research has demonstrated that CRC "arises as a consequence of the accumulation of 
genetic and heritable changes in gene expressions that drive the transformation and 
progression of normal colonic epithelial cells to cancer" (Saif & Chu, 201 0). This 
transformation is known as tumorigenesis. Tumorigenesis is the term used to describe 
the time it takes for a polyp to transform into true cancer, with the average being eight to 
12 years (Saif & Chu, 2010). Polyps are non-cancerous growths in the rectum and colon. 
5 
Though most polyps will not become cancerous, detecting them and removing them can 
actually prevent cancer from occurring (ACS). The ACS (2011) recommends a 
colonoscopy be performed by the age of 50, as most CRCs develop from adenomatous 
polyps. Screening before age 50 is recommended for those at increased risk of 
developing CRC. Those included in this population are persons with a family history of 
CRC or certain medical conditions (ACS). The National Comprehensive Cancer 
Network (NCCN) Guidelines (2011) suggest that children of clients with CRC have their 
initial screening colonoscopy ten years prior to the age the client is at time of diagnosis. 
In other words, if the client was 43 years of age at the time of diagnosis, their children 
should be screened when they are 33 years of age. 
The ACS estimated that in 2011, approximately 141 ,210 people would be 
diagnosed with CRC, and 49,380 would die from the disease in the US. CRC incidence 
rates have been declining since the mid 1980' s, with a reported decline of 3% in men and 
2.3% in women. This decline has been largely due to the detection and removal of 
precancerous lesions as a result of colorectal screening (ACS, 2011). 
While rates have been declining among adults 50 years and older, the incidence of 
CRC has increased among adults younger than 50 years. The reasons for this increase are 
not entirely known but may reflect increasing trends in obesity and and/or unfavorable 
dietary patterns in children and young adults (ACS, 2011). Up to 25% of clients may 
have a personal or family history suggestive of an inherited syndrome (Pollock & Welsh, 
2011). 
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Colorectal Cancer: Treatment Overview 
Most people with colon cancer, especially in the early stage, are treated with 
surgery to remove the tumor (ACS, 2011). Rectal cancer is treated with surgery only, 
unless the cancer has spread to other areas. Combination radiation and chemotherapy are 
given to those rectal cancer clients with a risk of recurrence or known to have the cancer 
in other areas of the body. The ACS describes cancer surgery as the removal of a 
cancerous tumor. When a section of the colon or rectum is removed, the surgeon can 
usually reconnect the healthy parts, allowing the client to eliminate normally. For some 
clients, this connection is not possible and they will require a colostomy. A colostomy is 
formed when the surgeon makes an opening or stoma in the skin of the abdomen for 
waste to leave the body. A bag is utilized to collect the waste material. This bag has an 
adhesive backing, which makes the appliance adhere to the skin. According to the ACS 
(20 11 ), most clients who need a colostomy need it only temporarily to allow the colon or 
rectum to heal. After healing takes place, in approximately 6-8 weeks, the surgeon will 
reconnect the parts of the intestine and close the stoma. 
Chemotherapy 
Adjuvant chemotherapy (chemotherapy after surgery) or radiation may also be 
g1ven. The chemotherapy drugs most often used for the treatment of CRC are 
Fluorouracil, Oxaliplatin, Leucovorin and Irinotecan (Arcangelo & Peterson, 2006). 
Chemotherapy affects the cancer cells but also affects some cells normally found in the 
body. There are several side effects commonly experienced after receiving these 
chemotherapeutic agents. Side effects depend on the type of drug, the duration of 
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treatment, the amount taken and whether or not the treatment spans several days 
(Arcangelo & Peterson, 2006). Fluorouracil is used before and after surgery. Expected 
side effects include diarrhea, mouth sores, difficulty swallowing, poor appetite, decreased 
blood cell production, pain, and redness and blistering of the palms and soles of the feet. 
Oxaliplatin is used after surgery or in the case of metastatic disease. One very specific 
side effect clients experience is cold sensitivity or neuropathy. This side effect prevents 
clients from eating or drinking cold fluids, and/or frozen foods for a minimum of four 
days following treatment. Other side effects include decreased proprioception (the 
body's sense of movement and position), nausea, vomiting, diarrhea, and decreased blood 
cell production. Irinotecan is used in clients with metastatic CRC and can cause severe 
diarrhea and abdominal cramping. Leucovorin is folic acid, which enhances the 5-
fluorouracil (Up-To-Date). The ACS (2011) recommends treatment decisions be made 
collaboratively by the physician and dient. Physician and client must consider the best 
options for the stage of the cancer and location of the cancer as well as the risks and 
benefits of each treatment. 
Chemotherapy - Induced Side Effects 
Chemotherapy induces a wide array of side effects. For purposes of this literature 
review, only those side effects specific to the GI tract will be discussed. CINV is a very 
common side effect and is associated with a significant deterioration in QOL with 
impaired functional abilities (Rangwala et al. , 2012). The greatest impact on QOL occurs 
in clients with the poorest control of CINV (Rangwala et al. , 2012). Likun et al. (2011) 
surveyed clients who experienced more than two episodes of CINV. These clients stated 
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that nausea and vomiting were the most feared effects of the chemotherapy. The 
experience of CINV puts these clients at risk for serious metabolic disturbances, 
malnutrition, weight loss, depression, and increased risk of not completing treatment 
(Rangwala et al. , 2012). The likelihood ofCINV is dependent on the dose ofthe drug 
and the emetogenicity ofthe chemotherapeutic agents. The NCCN Guidelines (2011) 
define emetogenicity as the potential risk that a client will experience nausea and/or 
vomiting as a result of receiving this treatment. Repeated chemotherapy cycles and client 
risk factors significantly influence CINV. 
According to the NCCN Guidelines (2011), clients receiving moderately 
emetogenic chemotherapy are at risk for both acute and delayed nausea/vomiting. New 
classifications of drugs to manage these problematic symptoms include the Serotonin 5-
HT3 receptor antagonists plus dexamethasone. These drugs block the chemotherapy 
trigger zone in the brain, decreasing the chance individuals will experience CINV. Some 
of these drugs are Ondansetron, Palonosetronin, and Aloxi. 
Antiemetic therapy should be initiated before chemotherapy is begun and should 
be continued for the same length oftime as the duration ofthe emetic activity of the 
chemotherapeutic agent being used (NCCN Guidelines, 2011). In other words, the client 
receives antiemetic therapy prior to infusion of chemotherapy and receives antiemetic 
therapy for as long as the chemotherapy is causing the symptom. The chemotherapies 
generally administered to the client with CRC cause nausea for up to 3-5 days post 
treatment; thus antiemetic treatment for this side effect should last at least that long. 
These drugs have significantly improved the control of acute CINV, but delayed CINV 
remains a significant clinical problem (Navari, 2009). 
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The practitioner must decide which antiemetic drug is best for each client. If 
CINV is not treated, nausea can significantly affect a client's quality oflife, leading to 
poor compliance with further chemotherapy. Additionally, nausea and vomiting can 
result in metabolic imbalances, degeneration of the client' s performance status and 
mental status, wound dehiscence (the unexpected opening of an incision), and esophageal 
tears (NCCN Guidelines, 2011). 
One potential side effect of this class of drugs is constipation, a particularly 
problematic issue for clients with CRC. Use of these anti-nausea medications leads to 
increased rates of constipation; there is an 18-20% chance of constipation when 5-HT3 
inhibitors are prescribed (Farjardo et al. , 2006). Ondansetron is the drug of choice in 
CRC, and the associated risk of constipation is reported to be 18%-20% (Up-to-Date). 
The unpleasant symptom of constipation can significantly compound the physical and 
emotional discomfort experienced by clients. 
Constipation: Definition and Impact 
Constipation is a general term used to describe the difficulties that a client 
experiences with moving his or her bowels. There is no universally accepted definition 
of constipation (Heitkemper & Wolff, 2007). Healthcare providers typically define 
constipation as stool frequency of less than three bowel movements per week. A 
thorough history from the client is necessary as clients define constipation as straining, 
hard stool, feeling of incomplete evacuation, and nonproductive urgency (Rao & Go, 
2010). In addition to the thorough history, the practitioner performs an abdominal 
exam and digital rectal exam (Heitkemper & Wolff, 2007). Evidence in both disease-
specific and generic QOL instruments has shown that constipation is associated with 
impaired health-related QOL (Rao & Go, 2010). Clients reported lower scores for 
physical functioning, mental health, general health perception, and bodily pain when 
compared to clients with no constipation. Additionally, constipation is a significant 
driver of healthcare costs, being ranked among the top five most common physician 
diagnoses for gastrointestinal outpatient visits (Rao & Go, 2010). Constipation is a 
condition the clinician must take into consideration when evaluating clients with 
advanced illness (Librach, Bouvette, DeAngelis & Pereira, 201 0). 
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The goal of managing clients with constipation is not only to relieve the 
constipated state but also to prevent recurrence (Heitkemper & Wolff, 2007). Educating 
the client to increase fluid intake, exercise, and add fiber to the diet in addition to taking a 
stimulant laxative is recommended. The laxative is for short-term use only. Finding the 
cause of the constipation and eliminating it are the best options. There are no official 
guidelines dictating the order in which treatment options for clients with constipation 
should be administered. Despite the strides in evidence-based nursing, numerous gaps 
remain (Heitkemper & Wolff, 2007). Managing constipation in clients with CRC is an 
important nursing concern. 
Constipation in Clients with Colorectal Cancer 
Constipation is a problem of increased significance for clients with cancer in 
general, and for those with CRC in particular. A study by Wilson, Alexander, Kind, & 
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Phil (2006) that examined QOL issues in the CRC client, found that 21.9% reported 
problems with constipation. Constipation estimates in the general population range from 
2% to 28%, whereas 40% of the palliative care population has reported symptoms of 
constipation (Wilson et al. , 2006). The use of other medications such as pain medications 
contributes to the increased rates of constipation. Constipation has a demonstrated 
negative impact on QOL but improved treatment may lessen the negative impact on a 
client's life (Farjardo et al., 2006). 
CRC clients are at increased risk of developing constipation as well as other side 
effects. A comprehensive medical history and physical exam are vital components in the 
evaluation of clients who present with constipation (Fajardo et al., 2006). Determining 
the change in the pattern and frequency of bowel movements, stool consistency, and ease 
of stool passage provides some indication of the severity of constipation. The nurse can 
assist the client with recognizing early symptoms of constipation and, more importantly, 
proactively anticipate constipation when certain medications are given to treat either the 
cancer or the side effects of chemotherapy treatments (Farjardo et al., 2006). Of note, 
bulk laxatives are of limited use in the cancer client who often has difficulty maintaining 
an adequate volume of fluid and may exacerbate opiate-induced constipation (Farjardo et 
al., 2006). 
Reviewing all medications taken and educating clients about medications that 
would effectively treat constipation should occur at start of treatments and at each 
subsequent visit. It is essential to review the client's entire medication list during each 
visit, as this can help identify those medications, which could potentially cause 
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constipation, and knowing what medications the client is taking helps to avoid some 
side effects. The CNS needs to listen to client, analyze the challenges the oncology client 
faces when a particular symptom arises, and implement the appropriate treatment plan 
(Miakowski, 2011 ). 
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The Impact of the CNS on Management of Symptoms of Constipation 
The dimensions of the CNS role are expert clinician, consultant, educator, and 
researcher. The CNS cares for and improves outcomes of clients through three spheres of 
influence: the client/family, nursing/nursing practice, and organizational/systems sphere 
(McKinley, 2007). Direct clinical practice is central to the care of any complex or unique 
client. Each client is unique and may display numerous problems. A CNS working with 
clients with cancer would demonstrate competence in the care of the complex oncology 
client. The CNS would identify client problems, identify staff learning needs, and assist 
with developing a plan of care (POC) to address complex issues. Through clinical 
leadership and influence, the CNS implements strategies for change designed to improve 
client care (Client sphere) positively impacts nursing practice (Nursing/Nursing Practice 
sphere), and directly impacts the care of patients overall (Organization/Systems sphere) 
(McKinley, 2007). A study by Kim (2011) compared outcomes including pain, fatigue, 
anxiety, and satisfaction, health related-quality of life (HRQOL ), ease of access, and 
unexpected emergency room visits for patients with cancer in South Korea who were 
cared for by a CNS with clients with cancer who were not cared for by a CNS. No 
significant effects were observed on anxiety from of unexpected emergency room visits. 
CNS interventions were found to diminish some intensity scores of pain and fatigue, and 
to increase HRQOL, satisfaction with trustworthiness, and ease of access (Kim, 2011). 
An important role of the CNS working with clients undergoing chemotherapy is 
to provide maximal protection against CINV. The CNS collaborates with nurses, 
physicians, and other members of the health care team and has a good understanding of 
the knowledge and skills of other health care team members (McKinley, 2007). The 
CNS plays a key role in the liaison work with members of the multidisciplinary team as 
well as care providers in the community of referring agencies (Andreyev, Davidson, 
Gillespie, Allum, & Swarbrick, 2012). Effective collaboration is the result of clinical 
competence, effective communication, mutual trust, collegiality, and a favorable 
organizational structure (Hanson & Spross, 2005). 
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There have been many changes in the management of CINV over the last two 
decades and nurses and clinicians caring for the clients receiving chemotherapy have 
several classes of agents to choose from when ordering anti-emetics (Viale, 2006). The 
development ofthe 5-HT3 category of medications represents a significant advance in 
antiemetic therapy. These agents have been shown to be effective in controlling the acute 
nausea and/or vomiting associated with cancer chemotherapy (NCCN Guidelines, 2011 ). 
It is difficult to recommend a specific antiemetic regimen for each client. The CNS 
evaluates the effectiveness of the drug for each regimen. The CNS must then educate the 
client about expected side effects and direct the client in the appropriate management of 
these side effects (Fulton, Lyon, & Goudreau, 2010). 
When choosing a 5HT3, thorough assessment, including a history of constipation, 
must be considered especially in the CRC population. The ability to engage in rational 
and deliberate reasoning or clinical inquiry to effectively solve clinical problems in the 
nursing domain is one ofthe cornerstones of the CNS (Fulton et al. , 2010). The CNS is 
challenged to assess clients for signs and symptoms of constipation by overcoming 
communication barriers associated with discussion of bowel habits (Heitkemper & Wolff, 
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2007). Characteristics, such as age, ethnicity, and co-morbidities, should be 
considered because they may affect the presentation and/or treatment of symptoms. This 
type of approach communicates to the clients and their families that symptoms are 
important (Sousa, McDermott, & Weiss, 2011 ). Many clients are sensitive about 
discussing issues pertaining to bowel habits. Asking targeted questions pertaining to 
bowel habits and related symptoms helps generate dialogue and establish how the client 
defines constipation (Heitkemper & Wolff, 2007). Laxatives should be routinely started 
in clients predisposed to constipation (Rangwala et al, 2012). Rangwala recommends 
that clients should increase fluids and physical activity and those clinicians need to 
consider reversible causes of constipation such as concurrent use of multiple constipating 
medications or metabolic abnormalities (e.g hypercalcemia). Effective CNS practice 
requires a highly developed perspective that puts the nursing care of the client in the 
foreground of clinical reasoning, with medical problems and disease focused care as 
critical background context (Fulton et al. , 2010). 
The goal of this project was to examine the incidence of constipation in clients 
with colorectal cancer on 5-HT3 inhibitors and to identify treatments that are successful 
in managing constipation while maintaining effective control ofCINV. Next, the 
framework used to guide this proposed research will be discussed. 
Theoretical Framework 
Theory of Unpleasant Symptoms 
Nursing literature abounds with the admonition that knowledge development 
requires strong links among theory, research, and practice. Research-practice linkages 
have been more firmly established than those of nursing theory to research and practice 
(Lenz, Suppa, Gift, Pugh, & Milligan, 1995). The Theory ofUnpleasant Symptoms 
(Figure 1) represents a theory developed for practice from practice-based research. The 
Theory of Unpleasant Symptoms specifies that the experience of symptoms is 
multidimensional and incorporates the potential interactions of multiple symptoms 
(Sousa, et al. , 2011). 
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The Theory ofUnpleasant Symptoms (Lenz et al. , 1995) was initially published in 
1995 and then updated in 1997. The theory is based on the premise that there are 
commonalities in the experiences of different symptoms among different groups and in 
different situations. The theory was developed to integrate existing knowledge about a 
variety of symptoms to better prepare the nurses in symptom management (Lenz, Suppa, 
Gift, Pugh, & Mulligan, 1997). The Theory of Unpleasant Symptoms is a middle-range 
theory that can guide research and practice across multiple clinical populations. The 
Theory of Unpleasant Symptoms was proposed as a means of integrating information 
about a variety of symptoms and was developed through the collaborative effort of 
Physiologic 
Factors 
Normal systems 
( eg, cardiovascular) 
Pathologic problems 
( eg, infection) 
Energy substrate 
e , nutrition 
Psychologic 
Factors 
Mental state 
( eg, depression) 
Reaction to illness state 
( eg, social support) 
duration 
quality 
Symptom 
Performance 
Situational 
Factors 
Life style 
(eg, employment) 
Personal experiences 
(eg, sodal support) 
Functional status (eg, role performance) 
Cognitive functioning (eg, problem solving) 
Physical performance ( eg activity level) 
Figure I. Theory of Unpleasant Symptoms 
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clinical researchers. The assumption behind the theory is that there are sufficient 
commonalities among symptoms to warrant a theory that is not limited to one symptom 
(Lenz et al., 1997). The Theory of Unpleasant Symptoms has three major components: 
the symptoms that the individual is experiencing; influencing factors that give rise to or 
affect the nature of the symptom experience; and the consequences of the symptom 
experience (Lenz et al., 1997). Symptoms are conceptualized both individually and in 
combination with other symptoms. The theory asserts that more often multiple 
symptoms are experienced simultaneously. The Theory of Unpleasant Symptoms 
acknowledges that a symptom of given severity may be incapacitating to some clients, 
whereas it might be less bothersome to others (Sousa et al., 2011). Lenz et al. (1995) 
have argued that the theory is clinically applicable because it goes beyond symptom-
specific concepts and theories. This theory stimulates thinking about common factors 
that may influence more than one symptom, the way in which multiple symptoms interact 
with one another and affect performance, and interventions that would mitigate multiple 
symptoms (Sousa et al., 2011). 
Symptoms need to be assessed in terms of duration, intensity, distress, and 
quality. Influencing factors can be physiologic factors, psychological factors, and/or 
situational factors. Performance is described in terms of functional status, cognitive 
functioning, or physical performance. The Theory ofUnpleasant Symptoms helps nurses 
recognize the need to assess multiple aspects of symptoms including characteristics, the 
underlying cause, as well as the frequency, intensity, duration, quality, and distress felt by 
the client due to the symptoms. This theory should stimulate nurses to consider factors 
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that might influence more than one symptom and ways in which symptoms interact 
with each other (Lenz et al. , 1997). This theory was useful in guiding this research, as 
constipation is an important client problem in CRC. This research paper identifies cases 
of constipation caused by the medication provided to prevent another symptom. With 
numerous interrelated symptoms potentially impacting client function, QOL, and other 
health-related outcomes, this theory helps the CNS identify the multidimensional nature 
of this problem. 
Method 
Purpose 
The purpose of this project was to determine the incidence of constipation in 
clients with CRC prescribed 5-HT3 inhibitors and to identify treatments that are 
successful in managing constipation while maintaining effective control of CINV. 
Research Questions 
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The research questions were: What is the incidence of constipation in clients with 
colorectal cancer taking the 5-HT3 inhibitor, ondansetron? What treatments are 
successful in managing constipation in these clients while maintaining effective control 
ofCINV? 
Design 
A retrospective descriptive study design was utilized. 
Site 
This study was conducted at The Leonard and Adele R. Decof Cancer Center 
located in the Fain Building at The Miriam Hospital, Providence, R.I. The Decof Center 
is a comprehensive cancer center providing care to clients with cancer and blood 
disorders. 
Sample 
The sample was recruited from the database of clients who had been treated at the 
Decof Cancer Center and who met inclusion criteria. Inclusion criteria included clients 
who completed chemotherapy consisting of Oxaliplatin or Irinotecan, Fluorouracil, and 
Leucovorin with ondansetron over a period of 24 months prior to the study and also 
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experienced constipation as a result of receiving the antiemetic ondansetron. Clients 
who had been previously treated with chemotherapy were excluded, as well as clients 
with a documented history of constipation prior to receiving ondansetron, and those who 
did not receive ondansetron as part of the anti-nausea treatment for CRC .. 
Procedure 
Prior to data collection activities, the proposal was reviewed and approved by the 
Lifespan and Rhode Island College IRBs. Institutional permission was obtained from the 
Director of Cancer Services and Ambulatory Care at the Decof Center. All active records 
are stored on site. The researcher obtained a list of clients who had been prescribed 
Oxaliplatin or Irinotecan, Fluorouracil and Leucovorin from the pharmacy. The list was 
then submitted to the Medical Records Department for record retrieval. 
Records were first reviewed for eligibility requirements, and once determined 
data was collected using a researcher-developed data collection tool. 
Measurement 
A data collection tool was developed for this project. After IRB approval, the tool 
was pilot tested with three client records to assure completeness and usability. Data 
collected included: confirmed use of the drug ondansetron; whether the client was taking 
narcotics for pain management; age; the number of episodes of constipation; subjective 
complaints related to constipation; treatment to manage constipation including drugs 
prescribed to relieve constipation; and reported effectiveness of treatment. For purposes 
of this research, constipation was defined as having fewer than three bowel movements a 
week. Treatment for constipation was considered effective if the client had relief of 
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constipation with resulting bowel movement within 24 hours of utilizing the prescribed 
treatment. 
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Results 
Eighty-two medical records were reviewed to obtain a cohort of 25 subjects 
requiring treatment for constipation. Four records were excluded due to documented 
history of constipation. All data obtained was stored in a locked file to which only the 
researcher and faculty advisor had access and confidentiality of all data was maintained. 
Of the 82 records reviewed, 25 subjects were identified who had treatment for 
constipation. This result demonstrated a 32.8% rate of constipation. The reported risk of 
constipation related to the administration of ondansetron was 18%-20% (Up-To-Date). 
The average age of subjects receiving treatment for constipation was 51.8 years, 
with a range of 3 3 to 86 years of age. Although documentation addressing constipation 
was retrieved, the subjects' description of the effectiveness of treatment for constipation 
was absent. Thee average age of the subject reporting a complaint of constipation was 
70.4 years with a range of 31 to 76 years of age. The average age of the subject 
experiencing constipation was thus significantly higher than the average age of the cohort 
of subjects (51.8years). 
Twenty-one of the 25 subjects reported one episode of constipation (84%), with 
an average age of 57.3 years old. Two of the 25 subjects (8%) reported two and three 
episodes of constipation each. Twenty-one of 82 subjects (26%) were noted to have 
been prescribed narcotics for pain management. In those records, it was noted by the 
clinician that the constipation experienced by the subject was not related to the narcotic 
use, but to the ondansetron. 
The treatment of constipation was varied, as can be seen from Figure 2. 
30°/o 
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Figure 2: Medications providing effective relief of constipation for subjects receiving 
ondansetron for the management of CINV. 
The most frequently used medication was Miralax (n = 7), followed by Senna or 
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Senokot (n = 3) and Colace (n = 2). The remaining treatments were described as follows: 
one subject took Metamucil, one received intravenous fluids, one received antibiotics for 
an infection, and one took prune juice. Six of the 25subjects (24%) experiencing 
constipation either had the ondansetron discontinued or the dose reduced. There was no 
relationship between the number of treatments a subject received and number of episodes 
of constipation reported. The researcher noted the episodes of constipation were 
reported at varying times throughout the client's chemotherapeutic cycle. 
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Summary and Conclusions 
Constipation is a general term used to describe the difficulties a client experiences 
with moving his or her bowels. There is no universally accepted definition of 
constipation (Heitkemper & Wolff, 2007). Constipation is a problem of increased 
significance with cancer in general, and for those with CRC in particular. The purpose of 
this project was to determine the incidence of constipation in clients with CRC prescribed 
the 5-HT3 inhibitor ondansetron and to identify treatments that are successful in 
managing constipation while maintaining effective control ofCINV. This study was 
guided by the Theory of Unpleasant symptoms, developed by Lenz et al. ( 199 5; 1997), 
which specifies that the experience of symptoms is multidimensional and incorporates the 
potential interactions of multiple symptoms (Sousa et al., 2011). 
A retrospective chart review was conducted; 82 charts were reviewed and 25 
charts met the inclusion criteria. The data demonstrated a 32.8% rate of constipation, 
higher than the 18%-20% risk of constipation related to the administration of ondansetron 
that is reported in the literature (Up-To-Date). The treatment of constipation varied from 
client to client. The most frequently used medication was Miralax (28%) followed by 
Senna or Senokot (12%) and Colace (8%). 
This study was limited by factors associated with the retrospective design, in 
particular, by the fact that minimal documentation of client description of symptoms and 
treatment effectiveness was able to be identified. While 82 records were reviewed, the 
actual sample include 25 subjects. Gender had not been identified as a variable in the 
data collection tool and was unable to be retrieved. 
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The CNS cares for and improves outcomes of clients through three spheres of 
influence: the client/family, nursing/nursing practice, and organizational/systems sphere 
(McKinley, 2007). While constipation is a commonly experienced symptom overall, in 
the CRC it is a significant contributor to decreased QOL. The CNS plays an important 
role in the management of this key symptom in the client with CRC. The CNS first 
conducts a comprehensive history to determine the etiology of the constipation, and then 
evaluates the client individually and determines whether diagnostic procedures are 
needed. Throughout the treatment process, the CNS assesses for adequate oral intake, 
determines medication use and compliance, performs abdominal and rectal exams and 
advises clients regarding effective therapeutic strategies. A comprehensive bowel 
regimen should be implemented at the initial chemotherapy treatment, with 
documentation ofthe effect of the regimen and recommendations as necessary. The 
choice of laxative should be discussed with each client individually, identifying any 
product the client found successful in the past. The clinician should avoid prescribing 
bulk laxatives in this fragile oncology population. Additionally, a comprehensive bowel 
regimen should be implemented at the initial chemotherapy treatment with 
documentation of the effect of the regimen and recommendations as necessary. The 
choice of laxative should be discussed with each client individually identifying any 
product the client found successful in the past. The clinician should avoid prescribing 
bulk laxatives in this fragile oncology population (Farjardo et al. , 2006). 
Though the sample was limited, based on the results of this study this writer will 
recommend that clients with a history of constipation not be routinely prescribed the 
antiemetic ondansetron, and that rather other effective antiemetics be identified in the 
antiemetic treatment plan. Further research is needed in this area in order to more 
broadly generalize results. Limited documentation of the subjects' description of 
symptoms along with minimal provider notes referring to the effectiveness of treatment 
was evident in the logs. This is an identified area for improvement, since this data is 
important when planning future treatments and optimizing symptoms management. 
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Implications and Recommendations 
As the treatment of the client with CRC continues to evolve, it is the role of the 
CNS as a member of the multidisciplinary team to continue to improve client outcomes 
by minimizing multidimensional symptoms. As identified in the Theory of Unpleasant 
Symptoms (Lenz et al., 1995; 1997), symptoms are conceptualized both individually and 
in combination with other symptoms, and each need to be assessed in terms of duration, 
intensity, distress, and quality. Influencing factors can be physiologic, psychological 
and/or situational factors, so it is essential that the treatment plan be broad and 
comprehensive. Addressing sources of distress and considering each individual client, 
especially when symptom management is not successful, is essential to an individualized, 
client-centered approach to care. Key principles are broad assessment for symptoms and 
other sources of distress and prioritizing which symptoms are most affecting client's 
QOL (Dy & Apostol, 2010). 
The CNS plays a pivotal role in directing the care ofthe client with cancer, at the 
individual, institutional, local, and national levels. Advocacy for continued treatment 
advancements and research is critically needed. Continued research related to symptom 
management is needed overall and in the CRC population. In particular, constipation is a 
commonly experienced symptom in this group that is often minimized in practice and yet 
adversely affects QOL. Research should continue to explore strategies to improve QOL 
in this population and to better manage symptoms such as constipation that also threaten 
on-going compliance with chemotherapy regimens. While this project focused on the 
impact of one drug on constipation, further research related to contributors to this 
symptom and interventions, including evidence-based holistic regimens, should be 
explored. Research with diverse subjects, representative of the CRC population, is 
indicated. 
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The CNS has the potential to play a leadership role in the management of clients 
with CRC. The literature is robust related to management of nausea and vomiting 
associated with chemotherapy regimens; further work is needed related to management of 
the symptom of constipation. 
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